Roche Diagnostics Operations, Inc.

Roche Molecular Systems, Inc.

Ventana Medical Systems, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Monika Soukupova

Michael Schraeml

Michael Gerg

Christian Klein

Dieter Heindl

Herbert Von Der Eltz

Johann Karl

Alfred Mertens

Birgit Bossenmaier

Andrea Horsch

Ursula-Henrike Wienhues-Thelen

Dirk Block

Alfred Engel

Michael Tacke

Christian Birkner

Leopold Von Proff

Klaus Hallermayer

Rosemarie Kientsch-Engel

Patrick C Roche

Edelgard Anna Kaiser

Sebastian Dziadek

Volker Schmid

Peter Kastner

Ulrike Kurtkaya

Sandra Rutz

Christina Rabe

Sonja Fiesel

Marion Herrmann

Stefanie Kern

Birgit Klapperich

Ekaterina Manuilova

Christina Porzig

Claudio Sustmann

Christoph Rutz

Jan Van Dieck

Anna Edelgard Kaiser

The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

IGFBP7 for prediction of risk of AKI when measured prior to surgery

The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.

Antibodies recognizing genetic variants of NT-proBNP

A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

Detection of a posttranslationally modified polypeptide by a bivalent binding agent

The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.

Antibodies specifically binding to HER3

The invention provides a composition containing an aqueous liquid phase, bacterial cells, and an ionic compound dissolved in the liquid phase. The ionic compound is selected from the group consisting of 1-butyl-3-methyl-imidazolium-thiocyanate, 1-butyl-3-methyl-imidazolium-2(2-methoxy-ethoxy)ethylsulfate, 1-methyl-1-[4-(3-methyl-3H-imidazol-1-ium)-but-1-yl]-3H-imidazolium-di(toluylsulfate), and 1-butyl-3-methyl-imidazolium-octylsulfate. The compositions of the invention are advantageously used for preparing lysates of biological cells, particularly bacterial cells.

Reagents for lysis of bacterial cells

Growing community of inventors

Wessobrunn, Germany

Monika Soukupova